Synageva Biopharma Corp (GEVA) Financial Statements (2024 and earlier)

Company Profile

Business Address 33 HAYDEN AVE.
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments446,908488,382534,501575,218408,733435,477
Cash and cash equivalents82,65376,53770,453152,33162,137216,870
Short-term investments364,255411,845464,048422,887346,596218,607
Receivables2,0042,3232,2411,4461,3731,142
Prepaid expense1,238567740923958464
Other current assets3,6011,9912,1041,2178401,388
Other undisclosed current assets4,0816,8636,0556,7854,8194,757
Total current assets:457,832500,126545,641585,589416,723443,228
Noncurrent Assets
Property, plant and equipment31,55931,32430,36923,64717,21315,527
Long-term investments and receivables2,0003,7383,891   
Long-term investments2,0003,7383,891   
Intangible assets, net (including goodwill)10,53810,78211,10011,63712,02612,402
Goodwill8,5358,5358,5358,5358,5358,535
Intangible assets, net (excluding goodwill)2,0032,2472,5653,1023,4913,867
Restricted cash and investments2,2742,2362,2342,2311,987 
Other noncurrent assets4,2745,9746,1252,2311,987726
Other undisclosed noncurrent assets(4,274)(5,974)(6,125)(2,231)(1,987) 
Total noncurrent assets:46,37148,08047,59437,51531,22628,655
TOTAL ASSETS:504,203548,206593,235623,104447,949471,883
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities30,42828,01431,07619,20116,93214,777
Employee-related liabilities6,0935,5724,4482,7603,2443,090
Accounts payable2,6253,0084,6202,5122,4271,545
Accrued liabilities21,71019,43422,00813,92911,26110,142
Other liabilities908660641653  
Deferred revenue and credits    932321,835
Other undisclosed current liabilities(6,093)(5,572)(4,448)(2,760)(3,244)(3,090)
Total current liabilities:25,24323,10227,26917,18713,92013,522
Noncurrent Liabilities
Liabilities, other than long-term debt5,7215,4645,3524,8253,8281,573
Other liabilities5,7215,4645,3524,8253,8281,573
Total noncurrent liabilities:5,7215,4645,3524,8253,8281,573
Total liabilities:30,96428,56632,62122,01217,74815,095
Equity
Equity, attributable to parent473,239519,640560,614601,092430,201456,788
Common stock333333333131
Additional paid in capital920,333908,902901,535891,735684,468680,244
Accumulated other comprehensive income (loss)(240)(73)(51)(13)(59)16
Accumulated deficit(446,887)(389,222)(340,903)(290,663)(254,239)(223,503)
Total equity:473,239519,640560,614601,092430,201456,788
TOTAL LIABILITIES AND EQUITY:504,203548,206593,235623,104447,949471,883

Income Statement (P&L) ($ in thousands)

3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
Revenues
(Revenue, Net)
1,2371,3262,3431,5863,4741,369
Gross profit:1,2371,3262,3431,5863,4741,369
Operating expenses(58,543)(49,364)(52,656)(38,062)(34,418)(29,565)
Operating loss:(57,306)(48,038)(50,313)(36,476)(30,944)(28,196)
Nonoperating expense(1,015)(312)(9)(692)(458) 
Investment income, nonoperating(1,103)  (687)  
Other nonoperating income (expense)88(312)(9)(5)  
Loss from continuing operations before equity method investments, income taxes:(58,321)(48,350)(50,322)(37,168)(31,402)(28,196)
Loss from equity method investments(250)     
Other undisclosed income from continuing operations before income taxes1,39647987622,828 
Loss from continuing operations before income taxes:(57,175)(48,303)(50,224)(36,406)(28,574)(28,196)
Income tax expense(490)(16)(16)(18)  
Other undisclosed loss from continuing operations     (48) 
Loss from continuing operations:(57,665)(48,319)(50,240)(36,424)(28,622)(28,196)
Loss before gain (loss) on sale of properties:(57,665)(48,319)(50,240)(36,424)(28,622)(28,196)
Net loss:(57,665)(48,319)(50,240)(36,424)(28,622)(28,196)
Other undisclosed net income (loss) attributable to parent     (2,114)73
Net loss available to common stockholders, diluted:(57,665)(48,319)(50,240)(36,424)(30,736)(28,123)

Comprehensive Income ($ in thousands)

3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
Net loss:(57,665)(48,319)(50,240)(36,424)(28,622)(28,196)
Other undisclosed comprehensive loss     (10) 
Comprehensive loss:(57,665)(48,319)(50,240)(36,424)(28,632)(28,196)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(167)(22)(38)46(2,179)104
Comprehensive loss, net of tax, attributable to parent:(57,832)(48,341)(50,278)(36,378)(30,811)(28,092)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: